EOLS - NASDAQ
Evolus, Inc.
$6.03
-2.3%Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
At a Glance
Live Snapshoteols
Other Non-Current Liabilities
Last Annual Value
21.17M
3-Year CAGR
-19%
5-Year CAGR
-18%
10-Year CAGR
85%
Evolus, Inc. Competitors Analysis of Other Non-Current Liabilities
| Company | Other Non-Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Evolus, Inc. NASDAQ:EOLS | 21.17M | -16.4% | -13.8% | 85.5% | |
 Neurogene Inc. NASDAQ:NGNE | 479.00K | 33.1% | -69.4% | N/A | |
 Treace Medical Concepts, Inc. NASDAQ:TMCI | 58.63M | 1065.9% | 220.6% | N/A | |
 CeriBell, Inc. NASDAQ:CBLL | 106.00K | -91.0% | N/A | N/A | |
 Quantum-Si incorporated NASDAQ:QSI | 34.00K | -70.2% | -66.0% | N/A | |
 Enhabit, Inc. NYSE:EHAB | 100.00K | -57.5% | N/A | N/A | |
 Solid Biosciences Inc. NASDAQ:SLDB | 0.00 | N/A | N/A | N/A | |
 OrthoPediatrics Corp. NASDAQ:KIDS | 12.44M | 38.7% | -15.5% | N/A | |
 The Oncology Institute, Inc. NASDAQ:TOI | 12.88M | 46.7% | -28.5% | N/A |
Evolus, Inc. Fair Value Envelope
Related Guides
Continue your EOLS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.